Table 2. Yields and purity of At-211-labelled antibodies prepared with the automated process platform and purified either manually or on the platform; the antibodies were previously prepared as m-MeATE-conjugates.
| Initial activity (MBq) | Elution medium | Conjugated Antibody | Purification Method | Labelling yield (%) | Radiochemical Purity (%) | Specific activity (MBq/mg) |
|---|---|---|---|---|---|---|
| 509 | MeOH/NIS | Trastuzumab | Manual Nap10 | 55 | 97 | 560 |
| 456 | MeOH/NIS | Trastuzumab | Automatic HiTrap | 48 | 99 | 430 |
| 400 | MeOH/NIS | MX35 | Automatic PD10 | 56 | 95 | 446 |
| 219 | CHCl3* | Trastuzumab | Manual Nap10 | 64 | 96 | 280 |
| 215 | CHCl3* | Trastuzumab | Automatic HiTrap | 55 | 98 | 230 |
*CHCl3 was evaporated on the process platform before starting synthesis.